![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RGS3 |
Gene summary for RGS3 |
![]() |
Gene information | Species | Human | Gene symbol | RGS3 | Gene ID | 5998 |
Gene name | regulator of G protein signaling 3 | |
Gene Alias | C2PA | |
Cytomap | 9q32 | |
Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | A0A024R831 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5998 | RGS3 | SYSMH6 | Human | Oral cavity | OSCC | 2.44e-02 | 1.38e-01 | 0.1275 |
5998 | RGS3 | male-WTA | Human | Thyroid | PTC | 3.44e-08 | 6.17e-02 | 0.1037 |
5998 | RGS3 | PTC01 | Human | Thyroid | PTC | 6.66e-07 | 5.86e-02 | 0.1899 |
5998 | RGS3 | PTC04 | Human | Thyroid | PTC | 3.08e-07 | 1.71e-01 | 0.1927 |
5998 | RGS3 | PTC05 | Human | Thyroid | PTC | 3.57e-05 | 2.79e-01 | 0.2065 |
5998 | RGS3 | PTC06 | Human | Thyroid | PTC | 1.28e-09 | 3.00e-01 | 0.2057 |
5998 | RGS3 | PTC07 | Human | Thyroid | PTC | 6.25e-08 | 2.26e-01 | 0.2044 |
5998 | RGS3 | ATC09 | Human | Thyroid | ATC | 6.77e-03 | 1.53e-01 | 0.2871 |
5998 | RGS3 | ATC11 | Human | Thyroid | ATC | 5.78e-03 | 2.45e-01 | 0.3386 |
5998 | RGS3 | ATC12 | Human | Thyroid | ATC | 7.49e-32 | 8.21e-01 | 0.34 |
5998 | RGS3 | ATC13 | Human | Thyroid | ATC | 1.78e-42 | 1.46e+00 | 0.34 |
5998 | RGS3 | ATC1 | Human | Thyroid | ATC | 1.44e-03 | 1.86e-01 | 0.2878 |
5998 | RGS3 | ATC2 | Human | Thyroid | ATC | 1.13e-06 | 1.11e+00 | 0.34 |
5998 | RGS3 | ATC3 | Human | Thyroid | ATC | 1.98e-08 | 3.25e-01 | 0.338 |
5998 | RGS3 | ATC4 | Human | Thyroid | ATC | 6.66e-40 | 1.14e+00 | 0.34 |
5998 | RGS3 | ATC5 | Human | Thyroid | ATC | 1.65e-55 | 1.55e+00 | 0.34 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa043604 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa043605 | Colorectum | FAP | Axon guidance | 47/1404 | 182/8465 | 9.09e-04 | 5.20e-03 | 3.16e-03 | 47 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RGS3 | SNV | Missense_Mutation | novel | c.560A>T | p.His187Leu | p.H187L | P49796 | protein_coding | deleterious(0.05) | benign(0) | TCGA-A1-A0SQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD |
RGS3 | SNV | Missense_Mutation | c.1097N>A | p.Ser366Asn | p.S366N | P49796 | protein_coding | tolerated(0.38) | benign(0.031) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
RGS3 | SNV | Missense_Mutation | rs200679819 | c.676N>C | p.Ala226Pro | p.A226P | P49796 | protein_coding | tolerated(0.23) | possibly_damaging(0.908) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
RGS3 | SNV | Missense_Mutation | c.3491A>G | p.Gln1164Arg | p.Q1164R | P49796 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BH-A1EX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
RGS3 | SNV | Missense_Mutation | rs200679819 | c.676N>C | p.Ala226Pro | p.A226P | P49796 | protein_coding | tolerated(0.23) | possibly_damaging(0.908) | TCGA-D8-A1JI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
RGS3 | SNV | Missense_Mutation | c.2668N>A | p.Glu890Lys | p.E890K | P49796 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-E2-A1B4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD | |
RGS3 | SNV | Missense_Mutation | rs201175305 | c.110N>G | p.Asn37Ser | p.N37S | P49796 | protein_coding | tolerated_low_confidence(0.57) | benign(0) | TCGA-E9-A1R7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | fareston | SD |
RGS3 | SNV | Missense_Mutation | rs200679819 | c.676N>C | p.Ala226Pro | p.A226P | P49796 | protein_coding | tolerated(0.23) | possibly_damaging(0.908) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
RGS3 | deletion | Frame_Shift_Del | novel | c.2501delN | p.Met834ArgfsTer7 | p.M834Rfs*7 | P49796 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
RGS3 | SNV | Missense_Mutation | rs772200505 | c.1169N>A | p.Arg390Gln | p.R390Q | P49796 | protein_coding | deleterious(0.05) | probably_damaging(0.941) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |